These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 26486144)

  • 1. RNA Interference as a Therapeutic Strategy for the Treatment of Liver Diseases.
    Gonzalez-Rodriguez A; Valverde AM
    Curr Pharm Des; 2015; 21(31):4574-86. PubMed ID: 26486144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A perspective on RNA interference-based therapeutics for metabolic liver diseases.
    Alkhouri N; Gawrieh S
    Expert Opin Investig Drugs; 2021 Mar; 30(3):237-244. PubMed ID: 33470860
    [No Abstract]   [Full Text] [Related]  

  • 3. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small interfering RNA: Discovery, pharmacology and clinical development-An introductory review.
    Ranasinghe P; Addison ML; Dear JW; Webb DJ
    Br J Pharmacol; 2023 Nov; 180(21):2697-2720. PubMed ID: 36250252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review article: RNA interference--potential therapeutic applications for the gastroenterologist.
    Pellish RS; Nasir A; Ramratnam B; Moss SF
    Aliment Pharmacol Ther; 2008 May; 27(9):715-23. PubMed ID: 18248657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury.
    Marinho HS; Marcelino P; Soares H; Corvo ML
    Curr Pharm Des; 2018; 24(23):2692-2700. PubMed ID: 30084326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient intracellular delivery and multiple-target gene silencing triggered by tripodal RNA based nanoparticles: a promising approach in liver-specific RNAi delivery.
    Sajeesh S; Lee TY; Kim JK; Son DS; Hong SW; Kim S; Yun WS; Kim S; Chang C; Li C; Lee DK
    J Control Release; 2014 Dec; 196():28-36. PubMed ID: 25251899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic delivery of RNA interference activators for therapeutic application.
    Arbuthnot P; Ely A; Weinberg MS
    Curr Gene Ther; 2009 Apr; 9(2):91-103. PubMed ID: 19355867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene silencing of HIV-1 by RNA interference.
    Takaku H
    Antivir Chem Chemother; 2004 Mar; 15(2):57-65. PubMed ID: 15185724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain Targeting of siRNA via Intranasal Pathway.
    Mohanty C; Kundu P; Sahoo SK
    Curr Pharm Des; 2015; 21(31):4606-13. PubMed ID: 26486146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts.
    Grzelinski M; Urban-Klein B; Martens T; Lamszus K; Bakowsky U; Höbel S; Czubayko F; Aigner A
    Hum Gene Ther; 2006 Jul; 17(7):751-66. PubMed ID: 16839274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Running interference: prospects and obstacles to using small interfering RNAs as small molecule drugs.
    Dykxhoorn DM; Lieberman J
    Annu Rev Biomed Eng; 2006; 8():377-402. PubMed ID: 16834561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic face of RNAi: in vivo challenges.
    Borna H; Imani S; Iman M; Azimzadeh Jamalkandi S
    Expert Opin Biol Ther; 2015 Feb; 15(2):269-85. PubMed ID: 25399911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.
    DeVincenzo JP
    Early Hum Dev; 2009 Oct; 85(10 Suppl):S31-5. PubMed ID: 19833462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisense and RNA interference approaches to target validation in pain research.
    Kurreck J
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):179-87. PubMed ID: 15603251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference-based gene silencing in mice: the development of a novel therapeutical strategy.
    Spänkuch B; Strebhardt K
    Curr Pharm Des; 2005; 11(26):3405-19. PubMed ID: 16250844
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery.
    Golzio M; Mazzolini L; Ledoux A; Paganin A; Izard M; Hellaudais L; Bieth A; Pillaire MJ; Cazaux C; Hoffmann JS; Couderc B; Teissié J
    Gene Ther; 2007 May; 14(9):752-9. PubMed ID: 17344906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.